3rd ADC Toxicity Summit

Welcome to the 3rd ADC Toxicity Summit

"Toxicity is the killer of ADCs" and remains the primary challenge limiting ADC success in the clinic. From unpredictable off-target effects to non-translating toxicity profiles and dose-limiting toxicities, the industry must address key hurdles in preclinical models, patient selection, ADC design, and cross-disciplinary communication to accelerate the next wave of safer, more effective ADCs.

The 3rd ADC Toxicity Summit is the only industry-led event bringing together toxicology, pharmacology, translational science, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing, predicting, and mitigating toxicities to enhance ADC safety and clinical translation.

With insights from influential leaders such as AbbVie, AstraZeneca, Daiichi Sankyo, Genentech, Iksuda, JandJ, MacroGenics and more, this is your opportunity for in-depth discussions and world class presentations on maximizing the translational relevance of in vivo and in vitro studies, mitigating toxicities to extend clinical dose escalations, optimizing dosing regimens, navigating regulatory expectations for toxicity models and more...

Speakers: Andy Judd, Medicinal Chemist, Abbvie, Anna Engstrom, Senior Principal Scientist and Toxicologist Safety Assessment, Genentech, Carole Harbison, Associate Scientific Fellow, Pathology, Takeda Pharmaceutical, Grace Lytle, Executive Director, Ocular Medical, AbbVie, Jennifer Brown, Senior Director of Toxicology, MacroGenics, John Kwon, Associate Director, AstraZeneca, Julia Kristensson, Associate Director, Bicycle Therapeutics, Kristin Decker, Associate Director Pharmacology and Toxicology, Heidelberg Pharma, Megan Terral, Director of Scientific Operations, AxoSim, Neel Pasricha, Assistant Professor of Ophthalmology, University of Califorina, San Francisco, Nicolas Quesnot, Senior Scientist, Preclinical Safety, Debiopharm, Paolo Tarantino, Clinical Research Fellow, Dana-Farber Cancer Institute, Raymond Evers, Senior Director, Global Translational ADME, Translational PK/PD and Investigative Toxicology, Johnson and Johnson, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Ronnie Yeager, Project Director, Emerging Therapeutic Platforms Beacon, Abbvie, Sonia Jain, Research Associate Radiation Oncology, Mayo Clinic, Steve Everett, Chief Executive Officer, MaveriX Oncology, Yu-Tzu Tai, Associate Director, Oxford BioTherapeutics, Zenta Tsuchihashi, Senior Director, Clinical Safety and Pharmacovigilance, Daiichi Sankyo